Maria Patrizia Carrieri

Dr. Maria Patrizia Carrieri


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2011 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
MMM Million
M Million
MMMarie Maraninchi
Marie Maraninchi
MHM Henry
M Henry
FAF Armougom
F Armougom
HRH Richet
H Richet
Didier RaoultDidier Raoult
Didier Raoult
Obesity is associated with increased health risk and has been associated with alterations in bacterial gut microbiota, with mainly a reduction in Bacteroidetes, but few data exist at the genus and species level. It has been reported that the Lactobacillus and Bifidobacterium genus representatives may have a critical role in weight regulation as an anti-obesity effect in experimental models and humans, or as a growth-promoter effect in agriculture depending on the strains. To confirm reported gut alterations and test whether Lactobacillus or Bifidobacterium species found in the human gut are associated with obesity or lean status, we analyzed the stools of 68 obese and 47 controls targeting Firmicutes, Bacteroidetes, Methanobrevibacter smithii, Lactococcus lactis, Bifidobacterium animalis and seven species of Lactobacillus by quantitative PCR (qPCR) and culture on a Lactobacillus-selective medium. In qPCR, B. animalis (odds ratio (OR)=0.63; 95% confidence interval (CI) 0.39–1.01; P=0.056) and M. smithii (OR=0.76; 95% CI 0.59–0.97; P=0.03) were associated with normal weight whereas Lactobacillus reuteri (OR=1.79; 95% CI 1.03–3.10; P=0.04) was associated with obesity. The gut microbiota associated with human obesity is depleted in M. smithii. Some Bifidobacterium or Lactobacillus species were associated with normal weight (B. animalis) while others (L. reuteri) were associated with obesity. Therefore, gut microbiota composition at the species level is related to body weight and obesity, which might be of relevance for further studies and the management of obesity. These results must be considered cautiously because it is the first study to date that links specific species of Lactobacillus with obesity in humans.

15 February 2006 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MOMagali Olivier
Magali Olivier
ALAnita Langer√∏D
Anita Langer√∏D
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
JBJonas Bergh
Jonas Bergh
SKSigrid Klaar
Sigrid Klaar
ABAnne-Lise B√∏Rresen-Dale
Anne-Lise B√∏Rresen-Dale
To investigate the clinical value of somatic TP53 mutations in breast cancer, we assembled clinical and molecular data on 1,794 women with primary breast cancer with long-term follow-up and whose tumor has been screened for mutation in exons 5 to 8 of TP53 by gene sequencing. TP53 mutations were more frequent in tumors of ductal and medullar types, aggressive phenotype (high grade, large size, node positive cases, and low hormone receptor content) and in women 10 years; P < 0.0001) compared with patients with no such mutation. The prognostic value of TP53 mutation was independent of tumor size, node status, and hormone receptor content, confirming and reconciling previous findings in smaller series. Moreover, an interaction between TP53 mutation and progesterone receptor (PR) status was revealed, TP53 mutation combined with the absence of progesterone receptor being associated with the worst prognosis. Whereas previous studies have emphasized the fact that missense mutations in the DNA-binding motifs have a worse prognosis than missense mutations outside these motifs, we show that non-missense mutations have prognostic value similar to missense mutations in DNA-binding motifs. Nonetheless, specific missense mutants (codon 179 and R248W) seem to be associated with an even worse prognosis. These results, obtained on the largest series analyzed thus far, show that TP53 mutations identified by gene sequencing have an independent prognostic value in breast cancer and could have potential uses in clinical practice.

1 April 2006 in The Lancet
Verified
Journal Article
Closed access
LFLaurent Ferradini
Laurent Ferradini
AJArnaud Jeannin
Arnaud Jeannin
LPLoretxu Pinoges
Loretxu Pinoges
JIJacques Izopet
Jacques Izopet
DODidakus Odhiambo
Didakus Odhiambo
CBChris Brasher
Chris Brasher

1 July 2010 in The Lancet
Verified
Journal Article
Closed access
DWDaniel Wolfe
Daniel Wolfe
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
DSDonald Shepard
Donald Shepard

1 August 2001 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FFFlorence Fenollar
Florence Fenollar
PFPierre‐Edouard Fournier
Pierre‐Edouard Fournier
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
GHGilbert Habib
Gilbert Habib
TMThierry Messana
Thierry Messana
Didier RaoultDidier Raoult
Didier Raoult
Coxiella burnetii causes acute and chronic Q fever. To evaluate the risk factors of development of chronic endocarditis following Q fever and to asse

1 December 2001 in AIDS
Verified
Journal Article
Closed access
SDSégolène Duran
Ségolène Duran
MSMarianne Savès
Marianne Savès
BSBruno Spire
Bruno Spire
VCValérie Cailleton
Valérie Cailleton
ASAlain Sobel
Alain Sobel
CLCatherine Leport
Catherine Leport
In a sample of 277 patients included in the French APROCO cohort study who were initially adherent at follow-up visit 4 months after initiation of a protease inhibitor-containing regimen, 76.4% self-reported at least one lipodystrophy-related symptom and 30.0% failed to maintain adherence behaviour 20 months after enrolment. After multiple adjustment for other related factors, such as younger age, alcohol consumption and poor housing conditions, the number of self-reported lipodystrophy symptoms was independently associated with adherence failure.